Published in Eur J Pediatr on April 04, 2008
Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J Biol Chem (2012) 1.80
Emergent properties of proteostasis in managing cystic fibrosis. Cold Spring Harb Perspect Biol (2011) 1.24
Functional stability of rescued delta F508 cystic fibrosis transmembrane conductance regulator in airway epithelial cells. Am J Respir Cell Mol Biol (2009) 1.12
Airway surface liquid depth measured in ex vivo fragments of pig and human trachea: dependence on Na+ and Cl- channel function. Am J Physiol Lung Cell Mol Physiol (2009) 1.04
Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings. Appl Environ Microbiol (2011) 1.01
Salmeterol restores secretory functions in cystic fibrosis airway submucosal gland serous cells. Am J Respir Cell Mol Biol (2008) 0.94
Local modulation of cystic fibrosis conductance regulator: cytoskeleton and compartmentalized cAMP signalling. Br J Pharmacol (2013) 0.83
Structural and biophysical properties of a synthetic channel-forming peptide: designing a clinically relevant anion selective pore. Biochim Biophys Acta (2011) 0.79
Searching for a cure for cystic fibrosis. A 25-year quest in a nutshell. Eur J Pediatr (2015) 0.78
Disease-specific clinical trials networks: the example of cystic fibrosis. Eur J Pediatr (2016) 0.75
Cystic fibrosis in a Hispanic adolescent. Pediatr Pulmonol (2013) 0.75
Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science (1989) 40.22
The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science (1998) 19.92
Nonsense-mediated mRNA decay in health and disease. Hum Mol Genet (1999) 6.90
PTC124 targets genetic disorders caused by nonsense mutations. Nature (2007) 6.67
Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell (1993) 6.25
A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med (2006) 5.74
Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med (2006) 5.37
Structure and function of the CFTR chloride channel. Physiol Rev (1999) 4.82
Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med (1995) 4.82
Lung transplantation and survival in children with cystic fibrosis. N Engl J Med (2007) 4.57
Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med (2003) 4.43
Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA (2003) 4.31
Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered-ring macrolide with improved potency against gram-negative organisms. Antimicrob Agents Chemother (1987) 4.00
Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J (2005) 3.30
Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol (1997) 3.23
Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J (2000) 3.14
Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections. J Biol Chem (2005) 3.08
Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet (2002) 2.85
Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med (2007) 2.85
Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet (1998) 2.66
A novel host defense system of airways is defective in cystic fibrosis. Am J Respir Crit Care Med (2006) 2.61
Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest (2003) 2.54
Cystic fibrosis mortality and survival in the UK: 1947-2003. Eur Respir J (2006) 2.54
Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Lancet (2001) 2.51
Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science (2004) 2.39
Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med (2005) 2.29
Clinical outcome in relation to care in centres specialising in cystic fibrosis: cross sectional study. BMJ (1998) 2.22
Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol (2007) 2.16
Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax (2002) 2.15
Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2001) 2.11
A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR function. Am J Respir Crit Care Med (1998) 2.08
Adult cystic fibrosis. JAMA (2007) 2.01
alpha1-Antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J (2006) 1.98
High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr (2007) 1.86
The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol (2002) 1.85
Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med (2000) 1.78
A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. Cystic Fibrosis Foundation Prednisone Trial Group. J Pediatr (1995) 1.75
Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. Am J Respir Crit Care Med (2007) 1.75
Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice. Antimicrob Agents Chemother (2007) 1.71
Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros (2005) 1.71
Quorum-sensing blockade as a strategy for enhancing host defences against bacterial pathogens. Philos Trans R Soc Lond B Biol Sci (2007) 1.70
Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J Pediatr (1995) 1.70
Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. Am J Physiol Cell Physiol (2001) 1.68
Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatr (1988) 1.66
Anti-inflammatory activity of macrolides: a new therapeutic potential? J Antimicrob Chemother (1998) 1.66
From registry to quality management: the German Cystic Fibrosis Quality Assessment project 1995 2006. Eur Respir J (2007) 1.61
Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial. Thorax (2006) 1.52
Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther (2007) 1.47
High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci U S A (2006) 1.47
Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol (2007) 1.46
Pharmacology of INS37217 [P(1)-(uridine 5')-P(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt], a next-generation P2Y(2) receptor agonist for the treatment of cystic fibrosis. J Pharmacol Exp Ther (2002) 1.40
Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains. J Biol Chem (2006) 1.39
Prospective, controlled study of a polyvalent pseudomonas vaccine in cystic fibrosis--three year results. Arch Dis Child (1984) 1.35
Rescue of DeltaF508 and other misprocessed CFTR mutants by a novel quinazoline compound. Mol Pharm (2005) 1.35
Phase 2 randomized safety and efficacy trial of nebulized denufosol tetrasodium in cystic fibrosis. Am J Respir Crit Care Med (2007) 1.32
Pharmacologic therapy for stop mutations: how much CFTR activity is enough? Curr Opin Pulm Med (2004) 1.28
Potential impact of newborn screening for cystic fibrosis on child survival: a systematic review and analysis. J Pediatr (2006) 1.28
A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients. Proc Natl Acad Sci U S A (2007) 1.27
Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis. Am J Respir Cell Mol Biol (2002) 1.26
Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med (2003) 1.24
Update on pathogenesis of cystic fibrosis lung disease. Curr Opin Pulm Med (2003) 1.20
The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J (1999) 1.18
Inhalation of Moli1901 in patients with cystic fibrosis. Chest (2007) 1.13
Genotype-phenotype correlations in cystic fibrosis. Pediatr Pulmonol (1996) 1.12
Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF. European Epidemiologic Registry of Cystic Fibrosis. Eur Respir J (2001) 1.11
Restoration of W1282X CFTR activity by enhanced expression. Am J Respir Cell Mol Biol (2007) 1.10
Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediatr Infect Dis J (2004) 1.09
SERCA pump inhibitors do not correct biosynthetic arrest of deltaF508 CFTR in cystic fibrosis. Am J Respir Cell Mol Biol (2005) 1.08
Genotypic characterization of Pseudomonas aeruginosa strains recovered from patients with cystic fibrosis after initial and subsequent colonization. Pediatr Pulmonol (2001) 1.08
Does centralized treatment of cystic fibrosis increase the risk of Pseudomonas aeruginosa infection? Acta Paediatr Scand (1986) 1.07
Potential of macrolide antibiotics to inhibit protein synthesis of Pseudomonas aeruginosa: suppression of virulence factors and stress response. J Infect Chemother (2000) 1.04
Gene therapy for cystic fibrosis lung disease: current status and future perspectives. Curr Opin Mol Ther (2006) 1.04
Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett (2006) 1.04
The use of human deoxyribonuclease (rhDNase) in the management of cystic fibrosis. BioDrugs (2005) 1.03
Effect of subinhibitory concentrations of macrolides on expression of flagellin in Pseudomonas aeruginosa and Proteus mirabilis. Antimicrob Agents Chemother (2000) 1.02
A phase I trial of intranasal Moli1901 for cystic fibrosis. Chest (2004) 1.00
Survival of lung transplant patients with cystic fibrosis harboring panresistant bacteria other than Burkholderia cepacia, compared with patients harboring sensitive bacteria. J Heart Lung Transplant (2007) 1.00
Sildenafil (Viagra) corrects DeltaF508-CFTR location in nasal epithelial cells from patients with cystic fibrosis. Thorax (2005) 0.98
A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics (2007) 0.98
Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function. Pediatrics (2007) 0.95
Correction of the CF defect by curcumin: hypes and disappointments. Bioessays (2005) 0.94
A phase I randomized, multicenter trial of CPX in adult subjects with mild cystic fibrosis. Pediatr Pulmonol (2002) 0.94
Calcium homeostasis is abnormal in cystic fibrosis airway epithelial cells but is normalized after rescue of F508del-CFTR. Cell Calcium (2007) 0.92
Influence of neonatal screening and centralized treatment on long-term clinical outcome and survival of CF patients. Eur Respir J (2001) 0.92
Activation of deltaF508 CFTR in a cystic fibrosis respiratory epithelial cell line by 4-phenylbutyrate, genistein and CPX. Eur Respir J (2000) 0.90
Cystic fibrosis transmembrane conductance regulator and the etiology and pathogenesis of cystic fibrosis. FASEB J (1992) 0.90
Gene therapy progress and prospects: cystic fibrosis. Gene Ther (2006) 0.90
Lung transplantation for cystic fibrosis: current concepts and one center's experience. J Cyst Fibros (2007) 0.90
Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis. J Med Chem (2006) 0.89
Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics. Am J Respir Med (2003) 0.89
Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J Cyst Fibros (2006) 0.89
Evaluation of different compounds as quorum sensing inhibitors in Pseudomonas aeruginosa. J Chemother (2007) 0.89
Inhaled corticosteroids for cystic fibrosis. Cochrane Database Syst Rev (2000) 0.87
Prediction of cellular immune responses against CFTR in patients with cystic fibrosis after gene therapy. Am J Respir Cell Mol Biol (2007) 0.87
Influence of macrolides on mucoid alginate biosynthetic enzyme from Pseudomonas aeruginosa. Clin Microbiol Infect (1997) 0.87
Cytokines and inflammatory mediators in cystic fibrosis. J Cyst Fibros (2004) 0.87
Pharmacotherapy of the ion transport defect in cystic fibrosis. Clin Exp Pharmacol Physiol (2001) 0.83
Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. Pediatr Pulmonol (2001) 0.82
Genetics and pulmonary medicine. 1. The genetics of cystic fibrosis lung disease. Thorax (1998) 0.79
Do inhaled corticosteroids impair long-term growth in prepubertal cystic fibrosis patients? Eur J Pediatr (2006) 0.79
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med (2015) 5.51
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. Thorax (2011) 2.84
Mutations in the amiloride-sensitive epithelial sodium channel in patients with cystic fibrosis-like disease. Hum Mutat (2009) 1.71
Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am J Respir Crit Care Med (2010) 1.71
Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med (2011) 1.69
Coexistence of (partial) immune defects and risk of recurrent respiratory infections. Clin Chem (2006) 1.60
Coprescription of antibiotics and asthma drugs in children. Pediatrics (2011) 1.56
Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis-associated liver disease. Hepatology (2011) 1.43
Laboratory diagnosis of specific antibody deficiency to pneumococcal capsular polysaccharide antigens by multiplexed bead assay. Clin Immunol (2009) 1.32
Laboratory diagnosis of specific antibody deficiency to pneumococcal capsular polysaccharide antigens. Clin Chem (2007) 1.17
Human memory B lymphocyte subsets fulfill distinct roles in the anti-polysaccharide and anti-protein immune response. J Immunol (2008) 1.14
Primary ciliary dyskinesia, an orphan disease. Eur J Pediatr (2012) 1.14
Is the sensitivity of primary ciliary dyskinesia detection by ciliary function analysis 100%? Eur Respir J (2013) 1.09
Elevated expression of both mRNA and protein levels of IL-17A in sputum of stable Cystic Fibrosis patients. Respir Res (2010) 1.07
Dysbiosis of bifidobacteria and Clostridium cluster XIVa in the cystic fibrosis fecal microbiota. J Cyst Fibros (2012) 1.04
Primary ciliary dyskinesia: critical evaluation of clinical symptoms and diagnosis in patients with normal and abnormal ultrastructure. Orphanet J Rare Dis (2014) 1.03
Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings. Appl Environ Microbiol (2011) 1.01
IL-12 contributes to allergen-induced airway inflammation in experimental asthma. J Immunol (2006) 1.01
Lung clearance index predicts pulmonary exacerbations in young patients with cystic fibrosis. Thorax (2013) 0.96
An international randomized multicenter comparison of nasal potential difference techniques. Chest (2010) 0.96
Non-invasive liver elastography (Fibroscan) for detection of cystic fibrosis-associated liver disease. J Cyst Fibros (2009) 0.92
Quality assessment of expert answers to lay questions about cystic fibrosis from various language zones in Europe: the ECORN-CF project. BMC Med Res Methodol (2012) 0.90
Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros (2012) 0.90
Distribution of human beta-defensin polymorphisms in various control and cystic fibrosis populations. Genomics (2005) 0.89
Toll-like receptor 2 and Toll-like receptor 4 polymorphisms in invasive pneumococcal disease. Microbes Infect (2006) 0.89
Impact of air pollution on cystic fibrosis pulmonary exacerbations: a case-crossover analysis. Chest (2013) 0.89
Exhaled nitric oxide corresponds with office evaluation of asthma control. Pediatr Pulmonol (2003) 0.88
Clinical practice: treatment of childhood empyema. Eur J Pediatr (2009) 0.87
A novel strategy for the isolation and identification of environmental Burkholderia cepacia complex bacteria. FEMS Microbiol Lett (2005) 0.86
Real life evaluation of intravenous antibiotic treatment in a paediatric cystic fibrosis centre: outcome of home therapy is not inferior. Respir Med (2008) 0.86
Successful management of severe respiratory failure combining heliox with noninvasive high-frequency percussive ventilation. Crit Care Med (2002) 0.86
Diagnostic accuracy of nitric oxide measurements to detect primary ciliary dyskinesia. Eur J Clin Invest (2014) 0.85
Omeprazole, a proton pump inhibitor, improves residual steatorrhoea in cystic fibrosis patients treated with high dose pancreatic enzymes. Eur J Pediatr (2003) 0.85
Tidal off-line exhaled nitric oxide measurements in a pre-school population. Eur J Pediatr (2003) 0.85
Fcgamma-receptor IIA genotype and invasive pneumococcal infection. Clin Immunol (2005) 0.84
Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma. Pediatr Allergy Immunol (2006) 0.84
Complicated parapneumonic effusion in Belgian children: increased occurrence before routine pneumococcal vaccine implementation. Eur J Pediatr (2008) 0.82
Pain in CF: review of the literature. J Cyst Fibros (2013) 0.80
Feasibility of non-invasive pressure support ventilation in infants with respiratory failure after extubation: a pilot study. Intensive Care Med (2009) 0.80
Hyper-immunoglobulin M syndrome caused by a mutation in the promotor for CD40L. Immunology (2007) 0.79
Airway clearance techniques to treat acute respiratory disorders in previously healthy children: where is the evidence? Eur J Pediatr (2008) 0.78
Granulomatous inflammation in cartilage-hair hypoplasia: risks and benefits of anti-TNF-α mAbs. J Allergy Clin Immunol (2011) 0.78
Misdiagnosis as asphyxiating thoracic dystrophy and CMV-associated haemophagocytic lymphohistiocytosis in Shwachman-Diamond syndrome. Eur J Pediatr (2013) 0.78
Treatment strategies for pulmonary sequestration in childhood: resection, embolization, observation? Acta Cardiol (2012) 0.78
Determination of IgG subclasses: a need for standardization. J Allergy Clin Immunol (2005) 0.78
Amoxicillin-clavulanic acid resistance in fecal Enterobacteriaceae from patients with cystic fibrosis and healthy siblings. J Cyst Fibros (2013) 0.77
Serum procalcitonin is not an early marker of pulmonary exacerbation in children with cystic fibrosis. Eur J Pediatr (2011) 0.77
Fold-increase in antibody titer upon vaccination with pneumococcal unconjugated polysaccharide vaccine. Clin Immunol (2012) 0.77
Communication of information about reproductive and sexual health in cystic fibrosis. Patients, parents and caregivers' experience. J Cyst Fibros (2011) 0.76
Unusual and severe disease course in a child with ataxia-telangiectasia. Pediatr Allergy Immunol (2003) 0.76
Nasal potential measurements on the nasal floor and under the inferior turbinate: does it matter? Pediatr Pulmonol (2010) 0.76
Lung transplantation in cystic fibrosis normalizes essential fatty acid profiles. J Cyst Fibros (2012) 0.76
Massive lung collapse with partial resolution after several years: a case report. BMC Pediatr (2005) 0.75
Cystic fibrosis: a balancing act? J Cyst Fibros (2006) 0.75
Has the hospital become the place not to be for infants with bronchiolitis? Eur J Pediatr (2012) 0.75
A 1-year old girl with fever and a unilateral swelling of the jaw. Eur J Pediatr (2004) 0.75
Comparison of lung clearance index measured during helium washin and washout in children with cystic fibrosis. Pediatr Pulmonol (2013) 0.75
Prenatal therapy for primary fetal hydrothorax in a dichorionic twin pregnancy. Prenat Diagn (2006) 0.75
Clinical outcome of parapneumonic empyema in children treated according to a standardized medical treatment. Eur J Pediatr (2014) 0.75
Influence of perfusate temperature on nasal potential difference. Eur Respir J (2012) 0.75